Complete Guide to peptides for weight loss in experimental research

Introduction: Why peptides are at the heart of obesity research

Obesity is a complex disease involving hormonal, neuroendocrine, and metabolic dysregulations that go far beyond a simple calorie imbalance. Peptides—small signaling molecules naturally present in the body—act precisely on these dysregulations: regulation of appetite, lipid metabolism, energy expenditure, and insulin sensitivity.

Research on weight loss peptides has seen a unprecedented acceleration Since 2020, driven by the clinical successes of Semaglutide and Tirzepatide, which demonstrated that weight reductions of >15% were achievable pharmacologically, Retatrutide (>20%) and next-generation molecules are pushing these limits even further.

Category 1 — Incretin agonists (GLP-1, GIP, Glucagon)

This is the most powerful and clinically documented family for body weight reduction.

Semaglutide — GLP-1 mono-agonist

Le Semaglutide It is a native GLP-1 analog with 94% homology, conjugated to a C18 diacid chain which gives it a half-life of ~7 days (weekly administration). It reduces appetite primarily via GLP-1 receptors in the hypothalamus and slows gastric emptying.

• Average weight loss: -15,2% in 68 weeks (STEP-1 study, 2021)
• Improvement in blood sugar, lipids and blood pressure
• Tolerance: frequent nausea and vomiting during the titration phase

Tirzepatide — Dual GLP-1/GIP agonist

Le Tirzepatide (LY3298176) is a dual GLP-1/GIP agonist, developed by Eli Lilly. The addition of the GIP agonist potentiates the insulinotropic effect and improves insulin sensitivity in adipose tissue.

• Weight loss: -22,5% at a dose of 15 mg over 72 weeks (SURMOUNT-1)
• HbA1c reduction greater than insulin in T2DM studies
• FDA approval (Zepbound) for obesity in 2023

Retatrutide — GLP-1/GIP/Glucagon triple agonist

Le Retatrutide (LY3437943) represents the cutting edge of current research. The addition of glucagon agonism to the two previous receptors increases basal energy expenditure and hepatic lipolysis — a fundamental mechanistic difference.

• Weight loss: -24,2% over 48 weeks at 12 mg (phase 2, NEJM 2023)
• Reduction of liver fat by -82% (MRI-PDFF)
• TRIUMPH Phase 3 program underway

→ Read the complete guide on Retatrutide

Category 2 — Growth hormone (GH) fragments

AOD-9604 — GH Fragment 176-191

L’AOD-9604 (Advanced Obesity Drug) is a synthetic fragment of amino acids 176-191 of human GH. Unlike complete GH, it has no effect on growth or blood glucose, but is said to retain the lipolytic properties of GH.

Its supposed mechanism involves the activation of beta-3 adrenergic receptors in adipose tissue, stimulating lipolysis and inhibiting lipogenesis.

• Studies in rats and mouse models: significant reduction in fat mass
• Human clinical trials (phase 2a, 2004): modest, inconclusive results
• No effect on IGF-1 or blood glucose — favorable preclinical safety profile
• Used in research to understand GH-independent lipolytic pathways

Ipamorelin + CJC-1295 — GH Secretagogues

The combination Ipamorelin (selective ghrelin agonist) + CJC-1295 (GHRH analogue) stimulates the physiological secretion of GH by the pituitary gland. The released GH promotes lipolysis and the preservation of lean mass, particularly during calorie restriction.

• Particular interest in research on body composition (fat mass/lean mass ratio)
• Effect on visceral lipolysis > subcutaneous according to some studies
• No direct hypoglycemic effect (unlike insulin)

→ Read the CJC-1295 + Ipamorelin guide

Category 3 — Hypothalamic-acting peptides

c-WORDs — Mitochondrial peptide

Le WORDS-c is a peptide from the mitochondrial genome (12S rRNA), identified in 2015. Studies in mice show that it improves insulin sensitivity, reduces high-fat diet-induced obesity, and increases spontaneous physical activity.

• Mechanism: activation of the AMPK pathway in muscle and adipose tissue
• Reduction of insulin resistance in diabetic mouse models
• Few human studies to date — an emerging field

Humanin — Cytoprotective mitochondrial peptide

L’Humanin is another mitochondrial peptide that improves insulin sensitivity and reduces apoptosis in pancreatic islets. Preclinical studies suggest a role in the regulation of glucose and fat mass.

Category 4 — Peptides with indirect metabolic action

BPC-157 — Gastric Protection and Metabolism

Le BPC-157 (Body Protection Compound-157), primarily known for its effects on wound healing and gastric protection, also presents interesting data on lipid metabolism and regulation of the gut-brain axis in some preclinical models.

→ Read the complete BPC-157 guide

Tesofensine — Triple reuptake inhibitor

La Tesofensine It is a triple reuptake inhibitor of serotonin, dopamine, and norepinephrine that reduces food intake through central action. Weight loss of -10% to -14% in phase 2. Classified as a peptide by convention, although technically a small molecule.

General comparative table

Common features of peptides studied for weight

Regardless of their specific mechanisms, the most effective peptides for body weight reduction in research share several characteristics:

• They act on several lanes simultaneously (multi-target > single-target)
• They preserve more of the lean mass than caloric approaches alone
• Their side effects are primarily gastrointestinal and dose-dependent.
• La long duration of action (half-life > 24h) is associated with better efficiency
• Efficiency is generally dose-dependent with a plateau relationship